Development & Functional Characterisation of Chimeric Engulfment Receptor (CER) T-Cells for the Treatment of Hematologic & Solid Malignancies

Time: 8:15 am
day: Day Two


  • New drug targets and next generation engineered T-cell products are needed to overcome current limitations of scFv- based CARs
  • Novel CER-T cell products leveraging naturally occurring phagocytic receptors represent a new class of cell therapy products targeting tumour stress ligands
  • Engulfment and enhanced APC-like function of CER-based products are hypothesised to overcome heterogeneous disease through recruitment of endogenous adaptive and innate anti-tumour immune response